Stable silk fibroin based pharmaceutical formulations
US10610478B2 · kind B2 · utility
9Cited by
27References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2018 |
| Grant date | Apr 7, 2020 |
| Priority date | — |
| Expiry date | Nov 8, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2800/75
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.